Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NAUT 
Nautilus Biotechnology Inc (NAUT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: NAUT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.5
1 Year Target Price $2.5
| 2 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -43.86% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 91.03M USD | Price to earnings Ratio - | 1Y Target Price 2.5 |
Price to earnings Ratio - | 1Y Target Price 2.5 | ||
Volume (30-day avg) 4 | Beta 1.24 | 52 Weeks Range 0.62 - 3.09 | Updated Date 09/14/2025 |
52 Weeks Range 0.62 - 3.09 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.52 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.3% | Return on Equity (TTM) -31.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -28661899 | Price to Sales(TTM) - |
Enterprise Value -28661899 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2 | Shares Outstanding 126305000 | Shares Floating 51283669 |
Shares Outstanding 126305000 | Shares Floating 51283669 | ||
Percent Insiders 33.5 | Percent Institutions 46.34 |
Upturn AI SWOT
Nautilus Biotechnology Inc
Company Overview
History and Background
Nautilus Biotechnology Inc. was founded in 2016 with the goal of revolutionizing proteomics by developing a single-molecule protein analysis platform. The company went public through a SPAC merger in 2021.
Core Business Areas
- Protein Analysis Platform Development: Nautilus is focused on developing and commercializing a platform for single-molecule protein analysis. This platform aims to provide high-throughput, low-cost proteomic data.
- Consumables and Reagents: Once the platform is launched, Nautilus will generate revenue through the sale of consumables and reagents required to run the platform.
Leadership and Structure
The company is led by Sujal Patel (CEO). The organizational structure includes departments focused on research and development, engineering, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Nautilus Proteomic Analysis Platform (In Development): The Nautilus platform is not yet commercially available. Competitors in proteomics technologies include companies using mass spectrometry such as Thermo Fisher Scientific (TMO) and Bruker (BRKR), as well as antibody-based assay companies such as Quanterix (QTRX). Market share data is not applicable as the product is pre-revenue.
Market Dynamics
Industry Overview
The proteomics market is experiencing growth driven by increasing demand for personalized medicine and biomarker discovery. High-throughput technologies are gaining prominence.
Positioning
Nautilus aims to disrupt the proteomics market with its single-molecule platform, offering potentially higher sensitivity and throughput than existing methods. It is positioned as an innovator in next-generation proteomics.
Total Addressable Market (TAM)
The total addressable market for proteomics is estimated to be in the billions of dollars. Nautilus is positioned to capture a portion of this market with its novel platform, pending successful commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary single-molecule protein analysis technology
- Strong intellectual property portfolio
- Experienced leadership team
- Potential for high-throughput and low-cost proteomics
Weaknesses
- Pre-revenue company with no commercial product yet
- High cash burn rate
- Technology still in development phase
- Reliance on successful product launch
Opportunities
- Growing demand for proteomics in drug discovery and diagnostics
- Potential for partnerships with pharmaceutical companies
- Expansion into new markets and applications
- Further technological advancements in protein analysis
Threats
- Competition from established proteomics companies
- Technological challenges in platform development
- Regulatory hurdles for diagnostic applications
- Potential for delays in product launch
Competitors and Market Share
Key Competitors
- TMO
- BRKR
- QTRX
Competitive Landscape
Nautilus has a potentially disruptive technology but faces competition from established players with existing market share and revenue streams. Nautilus advantages is better sensitivity, and more rapid data collection. Their disadvantage is the platform is not yet proven and commercialized.
Growth Trajectory and Initiatives
Historical Growth: No historical growth as the company is pre-revenue.
Future Projections: Future growth depends on successful commercialization of the protein analysis platform. Analyst estimates vary but are generally optimistic about long-term potential.
Recent Initiatives: Recent initiatives include advancing the development of the Nautilus platform, expanding collaborations, and strengthening the intellectual property portfolio.
Summary
Nautilus Biotechnology is a pre-revenue company with a promising but unproven proteomic analysis platform. The company has a strong cash position but is burning through it quickly. Its future success depends on the successful commercialization of its platform and overcoming competition from established players. Investors should be aware of the inherent risks associated with investing in a pre-revenue company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (e.g., 10-K, 10-Q)
- Company Investor Presentations
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data is based on publicly available information and may not be completely accurate or up-to-date. Investing in biotechnology companies involves significant risks, including the risk of loss of principal.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nautilus Biotechnology Inc
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2021-06-10 | Co-Founder, CEO, President, Secretary & Director Mr. Sujal M. Patel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 128 | Website https://www.nautilus.bio |
Full time employees 128 | Website https://www.nautilus.bio | ||
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which include sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.